The role of microrna-1246 in the regulation of b cell activation and the pathogenesis of systemic lupus erythematosus

Clinical Epigenetics

Volumn 7, Issue 1, 2015, Pages

  Luo, Shuangyan ^a   Liu, Yu ^a   Liang, Gongping ^a   Hao, Ming ^a   Wu, Haijing ^a   Liang, Yunsheng ^a   Qiu, Xiangning ^a   Tan, Yixin ^a   Dai, Yong ^b   Yung, Susan ^c   Chan, Tak Mao ^c   Lu, Qianjin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b SHENZHEN PEOPLE'S HOSPITAL   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

AKT; B cell; Co stimulatory molecules; EBF1; Has miR 1246; P53; Systemic lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT; B7 ANTIGEN; CD28 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CD86 ANTIGEN; CELL PROTEIN; CORTICOSTEROID DERIVATIVE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EARLY B CELL FACTOR 1; IMMUNOGLOBULIN M ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MESSENGER RNA; MICRORNA; MICRORNA 1246; MICRORNA 1246 INHIBITOR; MICRORNA 126; MICRORNA 142 3P; MICRORNA 142 5P; PROTEIN INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN P53; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; GENE REPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION;

EID: 84927142829     PISSN: 18687075     EISSN: 18687083     Source Type: Journal    
DOI: 10.1186/s13148-015-0063-7     Document Type: Article

References (59)

1. Frieri M. Mechanisms of disease for the clinician: systemic lupus erythematosus. Ann Allergy Asthma Immunol. 2013;110:228–32.
2. Javierre BM, Richardson B. A new epigenetic challenge: systemic lupus erythematosus. Adv Exp Med Biol. 2011;711:117–36.
3. Mak A, Tay SH. Environmental factors, toxicants and systemic lupus erythematosus. Int J Mol Sci. 2014;15:16043–56.
4. Rekvig OP, Van der Vlag J. The pathogenesis and diagnosis of systemic lupus erythematosus: still not resolved. Semin Immunopathol. 2014;36:301–11.
5. Liu A, La Cava A. Epigenetic dysregulation in systemic lupus erythematosus. Autoimmunity. 2014;47:215–9.
6. Deng Y, Tsao BP. Advances in lupus genetics and epigenetics. Curr Opin Rheumatol. 2014;26:482–92.
7. Guo Y, Sawalha AH, Lu Q. Epigenetics in the treatment of systemic lupus erythematosus: potential clinical application. Clin Immunol. 2014;155:79–90.
8. Zhao M, Liu S, Luo S, Wu H, Tang M, Cheng W, et al. DNA methylation and mRNA and microRNA expression of SLE CD4+ T cells correlate with disease phenotype. J Autoimmun. 2014;54:127–36.
9. Shen N, Liang D, Tang Y, de Vries N, Tak PP. MicroRNAs–novel regulators of systemic lupus erythematosus pathogenesis. Nat Rev Rheumatol. 2012;8:701–9.
10. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell. 2009;136:642–55.
11. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11:597–610.
12. Yang JS, Lai EC. Alternative miRNA biogenesis pathways and the interpretation of core miRNA pathway mutants. Mol Cell. 2011;43:892–903.
13. van Kouwenhove M, Kedde M, Agami R. MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer. 2011;11:644–56.
14. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19:92–105.
15. Ma X, Liu Q. MicroRNAs in the pathogenesis of systemic lupus erythematosus. Int J Rheum Dis. 2013;16:115–21.
16. Yan S, Yim LY, Lu L, Lau CS, Chan VS. MicroRNA regulation in systemic lupus erythematosus pathogenesis. Immune Netw. 2014;14:138–48.
17. Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, et al. Requirement of bic/microRNA-155 for normal immune function. Science. 2007;316:608–11.
18. Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T, et al. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell. 2010;142:914–29.
19. Du C, Liu C, Kang J, Zhao G, Ye Z, Huang S, et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol. 2009;10:1252–9.
20. Zhu S, Pan W, Song X, Liu Y, Shao X, Tang Y, et al. The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-alpha. Nat Med. 2012;18:1077–86.
21. Zhao S, Wang Y, Liang Y, Zhao M, Long H, Ding S, et al. MicroRNA-126 regulates DNA methylation in CD4+ T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1. Arthritis Rheum. 2011;63:1376–86.
22. Ding S, Liang Y, Zhao M, Liang G, Long H, Zhao S, et al. Decreased microRNA-142-3p/5p expression causes CD4+ T cell activation and B cell hyperstimulation in systemic lupus erythematosus. Arthritis Rheum. 2012;64:2953–63.
23. Stittrich AB, Haftmann C, Sgouroudis E, Kuhl AA, Hegazy AN, Panse I, et al. The microRNA miR-182 is induced by IL-2 and promotes clonal expansion of activated helper T lymphocytes. Nat Immunol. 2010;11:1057–62.
24. Xiao C, Calado DP, Galler G, Thai TH, Patterson HC, Wang J, et al. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell. 2007;131:146–59.
25. Ponomarev ED, Veremeyko T, Barteneva N, Krichevsky AM, Weiner HL. MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-alpha-PU.1 pathway. Nat Med. 2011;17:64–70.
26. de Yebenes VG, Bartolome-Izquierdo N, Ramiro AR. Regulation of B-cell development and function by microRNAs. Immunol Rev. 2013;253:25–39.
27. Zhang Y, Liao JM, Zeng SX, Lu H. p53 downregulates Down syndrome-associated DYRK1A through miR-1246. EMBO Rep. 2011;12:811–7.
28. Liao JM, Zhou X, Zhang Y, Lu H. MiR-1246: a new link of the p53 family with cancer and Down syndrome. Cell Cycle. 2012;11:2624–30.
29. Takeshita N, Hoshino I, Mori M, Akutsu Y, Hanari N, Yoneyama Y, et al. Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br J Cancer. 2013;108:644–52.
30. Gyory I, Boller S, Nechanitzky R, Mandel E, Pott S, Liu E, et al. Transcription factor Ebf1 regulates differentiation stage-specific signaling, proliferation, and survival of B cells. Genes Dev. 2012;26:668–82.
31. Zhao M, Liu Q, Liang G, Wang L, Luo S, Tang Q, et al. E4BP4 overexpression: a protective mechanism in CD4+ T cells from SLE patients. J Autoimmun. 2013;41:152–60.
32. Wu XN, Ye YX, Niu JW, Li Y, Li X, You X, et al. Defective PTEN regulation contributes to B cell hyperresponsiveness in systemic lupus erythematosus. Sci Transl Med. 2014;6:246-299.
33. Hasegawa S, Eguchi H, Nagano H, Konno M, Tomimaru Y, Wada H, et al. MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer. Br J Cancer. 2014;111:1572–80.
34. Sun Z, Meng C, Wang S, Zhou N, Guan M, Bai C, et al. MicroRNA-1246 enhances migration and invasion through CADM1 in hepatocellular carcinoma. BMC Cancer. 2014;14:616.
35. Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, et al. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One. 2014;9:e92921.
36. Chen J, Yao D, Zhao S, He C, Ding N, Li L, et al. MiR-1246 promotes SiHa cervical cancer cell proliferation, invasion, and migration through suppression of its target gene thrombospondin 2. Arch Gynecol Obstet. 2014;290:725–32.
37. Lukin K, Fields S, Hartley J, Hagman J. Early B cell factor: regulator of B lineage specification and commitment. Semin Immunol. 2008;20:221–7.
38. Sigvardsson M, Akerblad P, Leanderson T. Early B cell factor interacts with a subset of kappa promoters. J Immunol. 1996;156:3788–96.
39. Fretz JA, Nelson T, Velazquez H, Xi Y, Moeckel GW, Horowitz MC. Early B-cell factor 1 is an essential transcription factor for postnatal glomerular maturation. Kidney Int. 2014;85:1091–102.
40. Garel S, Marin F, Grosschedl R, Charnay P. Ebf1 controls early cell differentiation in the embryonic striatum. Development. 1999;126:5285–94.
41. Hagman J, Ramirez J, Lukin K. B lymphocyte lineage specification, commitment and epigenetic control of transcription by early B cell factor 1. Curr Top Microbiol Immunol. 2012;356:17–38.
42. Bishop GA, Hostager BS. B lymphocyte activation by contact-mediated interactions with T lymphocytes. Curr Opin Immunol. 2001;13:278–85.
43. Chevrier S, Genton C, Malissen B, Malissen M, Acha-Orbea H. Dominant role of CD80-CD86 Over CD40 and ICOSL in the massive Polyclonal B cell activation mediated by LAT (Y136F) CD4 (+) T cells. Front Immunol. 2012;3:27.
44. Suvas S, Singh V, Sahdev S, Vohra H, Agrewala JN. Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma.J Biol Chem. 2002;277:7766–75.
45. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515–48.
46. Rau FC, Dieter J, Luo Z, Priest SO, Baumgarth N. B7-1/2 (CD80/CD86) direct signaling to B cells enhances IgG secretion. J Immunol. 2009;183:7661–71.
47. Koni PA, Bolduc A, Takezaki M, Ametani Y, Huang L, Lee JR, et al. Constitutively CD40-activated B cells regulate CD8 T cell inflammatory response by IL-10 induction. J Immunol. 2013;190:3189–96.
48. Kin NW, Sanders VM. CD86 regulates IgG1 production via a CD19-dependent mechanism. J Immunol. 2007;179:1516–23.
49. Menezes SM, Decanine D, Brassat D, Khouri R, Schnitman SV, Kruschewsky R, et al. CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis. J Neuroinflammation. 2014;11:18.
50. Dejica DI, Manea EM. Costimulatory molecule CD154 in systemic lupus erythematosus and rheumatoid arthritis. Therapeutic perspectives. Roum Arch Microbiol Immunol. 2006;65:66–74.
51. Van Gool SW, Vandenberghe P, de Boer M, Ceuppens JL. CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model. Immunol Rev. 1996;153:47–83.
52. Kow NY, Mak A. Costimulatory pathways: physiology and potential therapeutic manipulation in systemic lupus erythematosus. Clin Dev Immunol. 2013;2013:245928.
53. Limon JJ, Fruman DA. Akt and mTOR in B cell activation and differentiation. Front Immunol. 2012;3:228.
54. Liu Z, Liu H, Jiang J, Tan S, Yang Y, et al. PDGF-BB and bFGF ameliorate radiation-induced intestinal progenitor/stem cell apoptosis via AKT/p53 signaling in mice. Am J Physiol Gastrointest Liver Physiol. 2014;307:G1033–43.
55. Zhou Y, Zhen H, Mei Y, Wang Y, Feng J, Xu S, et al. PI3K/AKT mediated p53 down-regulation participates in CpG DNA inhibition of spontaneous B cell apoptosis. Cell Mol Immunol. 2009;6:175–80.
56. Patel RK, Mohan C. PI3K/AKT signaling and systemic autoimmunity. Immunol Res. 2005;31:47–55.
57. Font J, Cervera R. 1982 revised criteria for classification of systemic lupus erythematosus–ten years later. Lupus. 1993;2:339–41.discussion 343.
58. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1989;32:1107–18.
59. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35:630–40.